Germany· DE-A57-b2996cf402c55ca0
Naropin
A ropivacaine product containing ropivacaine hydrochloride, registered in Germany by Hexal Ag. The same ATC class is registered in 17 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Ropivacaine is registered in 17 of 19 countries.
Countries holding a registration under ATC N01BB09 (ropivacaine), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 10 of them publish a price we can compare per daily dose
Ropivacaine · ATC N01BB09
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Ropivacaine Hydrochloride
- Manufacturer
- Hexal Ag
- Country
- Germany (DE)
- ATC code
- N01BB09
- ATC class
- Ropivacaine
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
106 interactions on record for ropivacaine.
Graded by severity as the source publishes them — 46 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ropivacaine · interactions on record
106 records
- 46 moderate
- 46 minor
- 14 info
Most severe, free to view
- LidocainA01AE01moderate
- TetracainA01AE02moderate
- Obeticholic acidA05AA04moderate
- FostamatinibB02BX09moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N01BB09
Ropivacaine, as other registers publish it.
- FranceNAROPEINE 10 mg/ml, solution injectable en ampouleSANDOZ
- FranceNAROPEINE 2 mg/ml, solution injectable en ampouleASPEN PHARMA TRADING (IRLANDE)
- FranceNAROPEINE 2 mg/ml, solution injectable en pocheASPEN PHARMA TRADING (IRLANDE)
- FranceNAROPEINE 5 mg/ml, solution injectableASPEN PHARMA TRADING (IRLANDE)
- GermanyNaropinAspen Pharma Trading Limited
- United StatesNaropinFresenius Kabi USA, LLC
- United StatesNaropinFresenius Kabi USA, LLC
- United StatesNaropinFresenius Kabi USA, LLC
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d8575e11-6edf-4fce-9a51-5f3978da5317 GET /v1/drugs/d8575e11-6edf-4fce-9a51-5f3978da5317?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Epidural Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Ropivacaine Hydrochloride",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about ropivacaine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.